Cédric Bretonnière

Prof. Cédric Bretonnière

Nantes Université, Nantes, Pays de la Loire, France
+2
orcid
M.D., Ph.D.

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2018 in Critical Care
Verified
Journal Article
Open access
PDF file
ANAntoine Néel
Antoine Néel
AWAnaïs Wahbi
Anaïs Wahbi
BTBenoit Tessoulin
Benoit Tessoulin
JBJulien Boileau
Julien Boileau
DCDorothée Carpentier
Dorothée Carpentier
MHMohamed Hamidou
Mohamed Hamidou
Adult-onset Still disease (AOSD) is a rare systemic inflammatory disorder. A few patients develop organ complications that can be life-threatening. Our objectives were to describe the disease course and phenotype of life-threatening AOSD, including response to therapy and long-term outcome. A multicenter case series of intensive care medicine (ICU) patients with life-threatening AOSD and a systematic literature review. Twenty patients were included. ICU admission mostly occurred at disease onset (90%). Disease manifestations included fever (100%), sore throat (65%), skin rash (65%), and arthromyalgia (55%). Serum ferritin was markedly high (median: 29,110 ng/mL). Acute respiratory failure, shock and multiple organ failure occurred in 15 (75%), 10 (50%), and 7 (35%) cases, respectively. Hemophagocytosis was demonstrated in eight cases. Two patients died. Treatment delay was significant. All patients received corticosteroids. Response rate was 50%. As second-line, intravenous immunoglobulins were ineffective. Anakinra was highly effective. After ICU discharge, most patients required additional treatment. Literature analysis included 79 cases of AOSD with organ manifestations, which mainly included reactive hemophagocytic syndrome (42%), acute respiratory failure (34%), and cardiac complications (23%). Response rate to corticosteroids was 68%. Response rates to IVIgs, cyclosporin, and anakinra were 50%, 80%, and 100%, respectively. AOSD should be recognized as a rare cause of sepsis mimic in patients with fever of unknown origin admitted to the ICU. The diagnosis relies on a few simple clinical clues. Early intensive treatment may be discussed. IVIgs should be abandoned. Long-term prognosis is favorable.

3 June 2015 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
CBCédric Bretonnière
Cédric Bretonnière
CÉCédric
Cédric
MLMarc Leone
Marc Leone
CMChristophe Milési
Christophe Milési
BABernard Allaouchiche
Bernard Allaouchiche
JBJean-Pierre Bedos
Jean-Pierre Bedos

11 March 2011 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
CGChristophe Guitton
Christophe Guitton
NGNathalie Gérard
Nathalie Gérard
VSVéronique Sébille
Véronique Sébille
CBCédric Bretonnière
Cédric Bretonnière
OZOlivier Zambon
Olivier Zambon
Beatrice CharreauBeatrice Charreau
Beatrice Charreau

1 December 2015 in Critical Care
Verified
Journal Article
Open access
PDF file
CBCédric Bretonnière
Cédric Bretonnière
MJMathieu Jozwiak
Mathieu Jozwiak
CGChristophe Girault
Christophe Girault
PBPascal Beuret
Pascal Beuret
JTJean-Louis Trouillet
Jean-Louis Trouillet
CGChristophe Guitton
Christophe Guitton
Introduction: Bacterial meningitis among critically ill adult patients remains associated with both high mortality and frequent, persistent disability. Vancomycin was added to treatment with a third-generation cephalosporin as recommended by French national guidelines. Because animal model studies had suggested interest in the use of rifampin for treatment of bacterial meningitis, and after the introduction of early corticosteroid therapy (in 2002), there was a trend toward increasing rifampin use for intensive care unit (ICU) patients. The aim of this article is to report on this practice. Methods: Five ICUs participated in the study. Baseline characteristics and treatment data were retrospectively collected from charts of patients admitted with a diagnosis of acute bacterial meningitis during a 5-year period (2004–2008). The ICU mortality was the main outcome measure; Glasgow Outcome Scale and 3-month mortality were also assessed. Results: One hundred fifty-seven patients were included. Streptococcus pneumoniae and Neisseria meningitidis were the most prevalent causative microorganisms. The ICU mortality rate was 15 %. High doses of a cephalosporin were the most prevalent initial antimicrobial treatment. The delay between admission and administration of the first antibiotic dose was correlated with ICU mortality. Rifampin was used with a cephalosporin for 32 patients (ranging from 8 % of the cohort for 2004 to 30 % in 2008). Administration of rifampin within the first 24 h of hospitalization could be associated with a lower ICU survival. Statistical association between such an early rifampin treatment and ICU mortality reached significance only for patients with pneumococcal meningitis (p=0.031) in univariate analysis, but not in the logistic model. Conclusions: We report on the role of rifampin use for patients with community-acquired meningitis, and the results of this study suggest that this practice may be associated with lower mortality in the ICU. Nevertheless, the only independent predictors of ICU mortality were organ failure and pneumococcal infection. Further studies are required to confirm these results and to explain how rifampin use would reduce mortality.

25 January 2012 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
CBClaire Boutoleau-Bretonnière
Claire Boutoleau-Bretonnière
TLThibaud Lebouvier
Thibaud Lebouvier
ODOdile Delaroche
Odile Delaroche
ELEstelle Lamy
Estelle Lamy
CEChristelle Evrard
Christelle Evrard
MVMartine Vercelletto
Martine Vercelletto
The objective of this study was to examine the diagnostic accuracy of imaging and CSF biomarkers in clinically ambiguous dementia (CAD). 69 patients were prospectively followed. The endpoint was clinical diagnosis at follow-up of 24 months based upon existing criteria. Medial temporal lobe atrophy score on MRI, distinctive patterns on 99 mTc-HMPAO-SPECT, and CSF levels of amyloid-β peptide, total tau protein, and P-tau181P were used together with neuropsychological testing to assess Se (sensitivity) and Sp (specificity) of separate and combined markers. 60 patients reached the endpoint. A definite diagnosis was achieved in 48 patients. CSF biomarkers had a Sp of 71% and a Se of 100% for Alzheimer's disease (AD) diagnosis. Sp increased to 88% and 93% when MRI and MRI + SPECT were combined, at the expense of Se. CSF biomarkers levels also provided clues to frontotemporal (FTD) or vascular dementias (VaD) diagnosis when situated in an intermediate range between normal and pathological values. MRI and SPECT contributed mostly to the diagnosis of VaD (Se 88%, Sp 75%) and FTD (Se 73%, Sp 78%), respectively. Initial neuropsychological testing had a poor diagnostic accuracy, except for a neuropsychiatric inventory score >40 for the diagnosis of FTD (Se 73%, Sp 84%). Independent of the clinical diagnosis, medial temporal lobe atrophy and total-tau were best correlated with cognitive decline at 2 years. In conclusion, CSF biomarkers efficiently predict evolution toward an AD phenotype in CAD. Imaging biomarkers mostly contribute to the differential diagnosis between non-AD dementias. Initial neuropsychological testing was poorly contributive in CAD diagnosis.

21 September 2010 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
CBCédric Bretonnière
Cédric Bretonnière
CJCédric Jacqueline
Cédric Jacqueline
JCJocelyne Caillon
Jocelyne Caillon
CGChristophe Guitton
Christophe Guitton
VMVirginie Le Mabecque
Virginie Le Mabecque
DBDavid Boutoille
David Boutoille
The aim of this study was to compare doripenem with imipenem and meropenem in an experimental rabbit model of Pseudomonas aeruginosa pneumonia and then to compare different doripenem doses and methods of intravenous administration. Using a rabbit experimental model of pneumonia, efficacy was assessed following 2 days of treatment by colony counts of different tissues (lung, spleen and blood culture). Mean pulmonary bacterial loads were 3.17 ± 0.53, 3.42 ± 0.61 and 2.75 ± 0.59 log10 cfu/g for imipenem, doripenem (0.5 g three times daily) and meropenem, respectively, compared with 7.57 ± 0.99 cfu/g for control animals. At a higher dose (1 g three times daily), doripenem showed significantly better efficacy (2.70 ± 0.65 log10 cfu/g) than the standard regimen of doripenem. Sterilization of spleen cultures was achieved with standard regimens of imipenem (1 g three times daily) and a higher dose of doripenem. In this model of P. aeruginosa pneumonia, doripenem had an efficacy equivalent to that of meropenem and imipenem at a high dose of 1 g three times a day and lower efficacy at a standard dose (0.5 g three times daily) than the other two agents in terms of bacteria cultivated from spleens. Doripenem is a new drug that offers new therapeutic options, especially for difficult-to-treat infections such as pneumonia due to non-fermenting Gram-negative bacteria.